Format
Sort by
Items per page

Send to

Choose Destination

Best matches for dyslipidemias AND pharmacotherapy:

Dyslipidemia and cardiovascular disease in women. Cífková R et al. Curr Cardiol Rep. (2015)

Atherogenic dyslipidemia and combination pharmacotherapy in diabetes: recent clinical trials. Hamilton SJ et al. Rev Diabet Stud. (2013)

Evolocumab in the treatment of dyslipidemia: pre-clinical and clinical pharmacology. Page MM et al. Expert Opin Drug Metab Toxicol. (2015)

Search results

Items: 1 to 20 of 26026

1.

Statins in adult patients with HIV: Protocol for a systematic review and network meta-analysis.

Roever L, Resende ES, Diniz ALD, Penha-Silva N, O'Connell JL, Gomes PFS, Zanetti HR, Roerver-Borges AS, Veloso FC, Fidale TM, Casella-Filho A, Dourado PMM, Chagas ACP, Ali-Hasan-Al-Saegh S, Reis PEO, Pinto RM, Oliveira GBF, Avezum Á, Neto M, Durães A, Silva RMFLD, Grande AJ, Denardi C, Lopes RD, Nerlekar N, Alizadeh S, Hernandez AV, Biondi-Zoccai G; Brazilian Network of Research in Meta-analysis (BRAMETIS).

Medicine (Baltimore). 2018 Apr;97(15):e0116. doi: 10.1097/MD.0000000000010116. Review.

2.

Fenofibrate monotherapy-induced rhabdomyolysis in a patient with hypothyroidism: A rare case report and literature review.

Wang D, Wang Y.

Medicine (Baltimore). 2018 Apr;97(14):e0318. doi: 10.1097/MD.0000000000010318. Review.

3.

Synthesis of Novel Benzimidazole-2-carboxamide Derivatives and in Vivo Antihyperlipidemic Activity Evaluation.

Sheikha GA, Bkhaitan MM, Kalloush H, Hamadneh L, Khalaf RA, Al-Qirim T, Al-Hiari Y.

Chem Pharm Bull (Tokyo). 2018;66(4):423-426. doi: 10.1248/cpb.c17-00908.

4.

Managing dyslipidaemia for the primary prevention of cardiovascular disease.

Ryan A, Heath S, Cook P.

BMJ. 2018 Mar 23;360:k946. doi: 10.1136/bmj.k946. Review. No abstract available.

PMID:
29572251
5.

Beneficial effects of paeoniflorin on osteoporosis induced by high-carbohydrate, high-fat diet-associated hyperlipidemia in vivo.

Wang Y, Zhu Y, Lu S, Hu C, Zhong W, Chai Y.

Biochem Biophys Res Commun. 2018 Apr 15;498(4):981-987. doi: 10.1016/j.bbrc.2018.03.093. Epub 2018 Mar 17.

PMID:
29550473
6.

Dietary Wheat Bran Oil Is Equally as Effective as Rice Bran Oil in Reducing Plasma Cholesterol.

Lei L, Chen J, Liu Y, Wang L, Zhao G, Chen ZY.

J Agric Food Chem. 2018 Mar 21;66(11):2765-2774. doi: 10.1021/acs.jafc.7b06093. Epub 2018 Mar 9.

PMID:
29502409
7.

PCSK9 inhibition in PAD patients - a rising star in secondary prevention?

[No authors listed]

Vasa. 2018 Feb;47(2):157. doi: 10.1024/0301-1526/a000690. No abstract available.

PMID:
29460708
8.

Inclisiran for the treatment of dyslipidemia.

Nishikido T, Ray KK.

Expert Opin Investig Drugs. 2018 Mar;27(3):287-294. doi: 10.1080/13543784.2018.1442435. Epub 2018 Feb 22. Review.

PMID:
29451410
9.

Development of vaccine for dyslipidemia targeted to a proprotein convertase subtilisin/kexin type 9 (PCSK9) epitope in mice.

Kawakami R, Nozato Y, Nakagami H, Ikeda Y, Shimamura M, Yoshida S, Sun J, Kawano T, Takami Y, Noma T, Rakugi H, Minamino T, Morishita R.

PLoS One. 2018 Feb 13;13(2):e0191895. doi: 10.1371/journal.pone.0191895. eCollection 2018.

10.

A keen eye for risk.

Ford TJ, Rocchiccioli P.

BMJ. 2018 Feb 1;360:j5884. doi: 10.1136/bmj.j5884. No abstract available.

PMID:
29419393
11.

PCSK9 inhibitors: a non-statin cholesterol-lowering treatment option.

Pokrywka GS.

Postgrad Med. 2018 Apr;130(3):287-298. doi: 10.1080/00325481.2018.1436843. Epub 2018 Feb 23. Review.

PMID:
29411675
12.

[Chinese expert consensus on the use of Xuezhikang (2017 revised edition)].

Committee of Cardio-Cerebro-Vascular Diseases of Gerontological Society of China; Working Group of Chinese Expert Consensus on the Use of Xuezhikang.

Zhonghua Nei Ke Za Zhi. 2018 Feb 1;57(2):97-100. doi: 10.3760/cma.j.issn.0578-1426.2018.02.003. Chinese.

PMID:
29397593
13.

Association between triglyceride levels and cardiovascular disease in patients with acute pancreatitis.

Copeland LA, Swendsen CS, Sears DM, MacCarthy AA, McNeal CJ.

PLoS One. 2018 Jan 30;13(1):e0179998. doi: 10.1371/journal.pone.0179998. eCollection 2018.

14.

5-aminosalicylic acid improves lipid profile in mice fed a high-fat cholesterol diet through its dual effects on intestinal PPARγ and PPARα.

Wang Z, Koonen D, Hofker M, Bao Z.

PLoS One. 2018 Jan 19;13(1):e0191485. doi: 10.1371/journal.pone.0191485. eCollection 2018.

15.

Improvement of endothelial function by pitavastatin: a meta-analysis.

Katsiki N, Reiner Ž, Tedeschi Reiner E, Al-Rasadi K, Pirro M, Mikhailidis DP, Sahebkar A.

Expert Opin Pharmacother. 2018 Feb;19(3):279-286. doi: 10.1080/14656566.2018.1428560. Epub 2018 Jan 18. Review.

PMID:
29334477
16.

Treatment Strategies for Hypercholesterolemia.

Hartz J, Clauss S.

Curr Pediatr Rev. 2017;13(4):243-254. doi: 10.2174/1573396314666180111143900. Review.

PMID:
29332588
17.

Dyslipidemia, chronic inflammation, and subclinical atherosclerosis in children and adolescents infected with HIV: The PositHIVe Health Study.

Augustemak de Lima LR, Petroski EL, Moreno YMF, Silva DAS, Trindade EBMS, Carvalho AP, Back IC.

PLoS One. 2018 Jan 10;13(1):e0190785. doi: 10.1371/journal.pone.0190785. eCollection 2018.

18.

Payer and Pharmaceutical Manufacturer Considerations for Outcomes-Based Agreements in the United States.

Brown JD, Sheer R, Pasquale M, Sudharshan L, Axelsen K, Subedi P, Wiederkehr D, Brownfield F, Kamal-Bahl S.

Value Health. 2018 Jan;21(1):33-40. doi: 10.1016/j.jval.2017.07.009. Epub 2017 Aug 30.

19.

Dyslipidaemia in the elderly: to treat or not to treat?

Katsiki N, Kolovou G, Perez-Martinez P, Mikhailidis DP.

Expert Rev Clin Pharmacol. 2018 Mar;11(3):259-278. doi: 10.1080/17512433.2018.1425138. Epub 2018 Jan 12. Review.

PMID:
29303009
20.

A Brief Drug Class Review: Considerations for Statin Use, Toxicity, and Drug Interactions.

Wooten JM.

South Med J. 2018 Jan;111(1):39-44. doi: 10.14423/SMJ.0000000000000752. Review.

PMID:
29298368

Supplemental Content

Loading ...
Support Center